Inpharma Weekly

, Volume 1122, Issue 1, pp 9–10 | Cite as

Selective COX-2 inhibitors gather speed

  • Amanda Cameron
Newsletter Article


Selective inhibitors of cyclo-oxygenase type 2 (COX-2) continue to tantalise rheumatologists with the promise of delivering the same anti-inflammatory and analgesic effects as those of conventional NSAIDs, without the adverse gastrointestinal (GI) effects commonly seen with these drugs. The results of clinical trials of two COX-2 inhibitors, Searle’s celecoxib and Merck’s MK 966, were presented at the recent National Scientific Meeting of the American College of Rheumatology [ Washington DC, US; November 1997 ]. These results add to the growing body of evidence supporting the efficacy of COX-2 inhibitors in reducing pain and inflammation to a similar degree as conventional NSAIDs. However, an improved long-term tolerability profile remains to be demonstrated over the traditional NSAIDs.


Celecoxib Naproxen Traditional NSAID Conventional NSAID Naproxen 500mg 

Copyright information

© Adis International Ltd 1998

Authors and Affiliations

  • Amanda Cameron

There are no affiliations available

Personalised recommendations